Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 238-248

  Hutmacher, Matthew M ^a   Nestorov, Ivan ^b   Ludden, Tom ^c   Zitnik, Ralph ^d   Banfield, Christopher ^d  

^a PFIZER INC   (United States)

^b ZYMOGENETICS INC   (United States)

^c ICON Development Solutions   (United States)

^d AMGEN INC   (United States)

Author keywords

Exposure response modeling; Generalized nonlinear mixed effects models; Logistic regression; NONMEM; Population pharmacokinetic pharmacodynamic (PK PD) modeling

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHOTOTHERAPY; PSORIASIS VULGARIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL ANALYSIS;

HUMANS; IMMUNOGLOBULIN G; MODELS, BIOLOGICAL; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 33846430457     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006295062     Document Type: Article

References (25)

1. Exposure-Response Relationships: Study Design, Data Analysis, and Regulatory Applications. FDA Guidance for Industry. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed April 2003.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996 ; 14: 485-496.
3. Granstein RD. New treatments for psoriasis. N Engl J Med. 2001 ; 345: 284-287.
4. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999 ; 38: 241-251.
5. Enbrel (etanercept) [prescribing information]. Thousand Oaks, Calif: Amgen, Inc and Wyeth-Ayerst Pharmaceuticals; 2006.
6. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003 ; 73: 348-365.
7. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005 ; 45: 246-256.
8. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004 ; 42: 267-276.
9. Nestorov I, Zitnik R, Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2004 ; 31: 463-490.
10. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 ; 139: 1627-1632.
11. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 ; 349: 2014-2022.
12. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 ; 152: 1304-1312.
13. Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol. 2006 ; 62: 435-445.
14. Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol. 2004 ; 44: 1244-1251.
15. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978 ; 157: 238-244.
16. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 ; 21: 735-750.
17. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. Pharmacokinet Pharmacodyn. 2003 ; 30: 387-404.
18. Beal SL, Sheiner LB. NONMEM User Guides. San Francisco: NONMEM Project Group, University of California ; 1996.
19. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther. 1996 ; 60: 619-635.
20. Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res. 2001 ; 18: 1210-1219.
21. Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994 ; 56: 309-322.
22. Sheiner LB, Beal SL, Dunne A. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Am Statist Assoc. 1997 ; 92: 1235-1244.
23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192.
24. Kowalski KG, McFadyen L, Hutmacher MM, Frame B, Miller R. A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn. 2003 ; 30: 315-336.
25. Meeks SL, D'Agostino RB. A note on the use of confidence limits following rejection of a null hypothesis. Am Stat. 1983 ; 37: 134-136.